Intimate regenerative medicine has become one of the most aggressively marketed sectors within modern med spas and urology clinics. Among these procedures, the "O-Shot" (Orgasm Shot) for women and the "P-Shot" (Priapus Shot) for men are widely advertised. Promoters promise significant improvements in sexual function, arousal, libido, and even urinary incontinence, often citing "success rates" between 75% and 94%.
However, behind the marketing slogans lies a complex landscape of regulatory classifications and clinical research. Patients and providers frequently ask: Are the O-Shot and P-Shot FDA-approved? Does injecting platelet-rich plasma (PRP) into intimate tissues actually work? What do the peer-reviewed clinical trials and systematic reviews demonstrate?
This article examines the clinical evidence, the mechanical pathways, the FDA clearance status of PRP devices, the specific clinical trials for both sexes, and the practical costs and safety profiles of these treatments.
What exactly are the O-Shot and P-Shot, and are they FDA-approved?
The O-Shot and P-Shot are clinical procedures that use autologous platelet-rich plasma (PRP). PRP is prepared by drawing a patient's own blood, placing it in a specialized centrifuge, and spinning it to separate the red blood cells from the plasma, concentrating the platelets. The resulting platelet-rich fraction, which contains high levels of growth factors (such as VEGF, PDGF, and TGF-beta), is then injected into specific anatomical zones:
- The O-Shot: Injected into the clitoral space and the anterior vaginal wall (the G-spot area).
- The P-Shot: Injected directly into the corpus cavernosum and glans of the penis.
[Patient Blood Draw] ──> [Centrifugation] ──> [Platelet-Rich Plasma (PRP) Isolation]
│
┌──────────────────────────────────────┴─────────────────────────────────────┐
▼ ▼
[O-Shot Injection] [P-Shot Injection]
Clitoral Space & Anterior Vaginal Wall Corpus Cavernosum & Glans
The Regulatory Reality: Cleared Devices vs. Off-Label Procedures
It is critical to distinguish between the devices used to prepare PRP and the procedures themselves:
- Centrifuge System Clearance: The FDA has cleared several commercial centrifuge systems and separation kits (such as the Magellan autologous platelet separator or the Harvest SmartPrep system) under 510(k) applications. These clearances are categorized under Class II medical devices. Crucially, these devices are cleared only for preparing PRP to be used in orthopedic bone grafts or hard/soft tissue wound healing.
- Procedure/Indication Approval: The FDA has not approved or cleared the O-Shot or P-Shot procedures, nor has it approved PRP for the treatment of sexual dysfunction or urinary incontinence.
Injecting PRP into clitoral, vaginal, or penile tissues constitutes an off-label use of a cleared medical device. While physicians have the legal right to practice medicine and use devices off-label, marketing these procedures as "FDA-approved for sexual enhancement" is a regulatory violation.
Additionally, "O-Shot" and "P-Shot" are not clinical terms; they are registered trademarks owned by Dr. Charles Runels, who licenses the names to practitioners who complete his training protocols.
Does the O-Shot work for women, and what do the trials actually show?
The marketing for the O-Shot suggests it is a highly successful treatment for Female Sexual Dysfunction (FSD)—which encompasses hypoactive sexual desire, arousal disorder, and female orgasmic disorder—as well as Stress Urinary Incontinence (SUI). However, independent scientific audits reveal a significant gap between marketing claims and registered clinical data.
The Registered Trial Landscape and FSFI Metrics
To characterize the true clinical benefit of the O-Shot, researchers rely on standardized clinical endpoints. The most widely accepted metric is the Female Sexual Function Index (FSFI), a 19-item questionnaire that measures sexual function across six specific domains:
- Desire: Frequency and level of sexual desire.
- Arousal: Frequency, level, and satisfaction with sexual arousal.
- Lubrication: Frequency, difficulty, and maintenance of lubrication.
- Orgasm: Frequency, difficulty, and satisfaction with orgasms.
- Satisfaction: Satisfaction with closeness to partner, sexual relationship, and overall sex life.
- Pain: Discomfort or pain during vaginal penetration.
Each domain is scored, and the individual domain scores are multiplied by a factor to yield a maximum total score of 36.0. A total FSFI score of 26.55 or lower is the established clinical threshold for diagnosing female sexual dysfunction.
To understand the evidence base, researchers have evaluated the history of clinical trial registrations for female intimate PRP. An audit conducted by Oklahoma State University (OSU) analyzed the ClinicalTrials.gov registry to track studies investigating PRP for female sexual dysfunction. The findings were revealing:
- Study Attrition: The researchers identified 18 registered clinical trials investigating PRP for female sexual dysfunction.
- Completion Rate: Only 33% (6 trials) of the registered studies were successfully completed.
- Evidence Deficiency: Out of the completed trials, only three published consistent safety and efficacy data in peer-reviewed journals.
- The Verdict: None of the completed, registered trials demonstrated a statistically significant improvement in sexual satisfaction, arousal, or orgasm compared to placebo or active control groups. While some patients reported improvements, these were within the margin of a standard placebo response. The review concluded that the clinical evidence remains highly preliminary and does not support the broad marketing claims made by licensing providers.
Systematic Review Verdicts
A comprehensive systematic review published in 2023 (PMC10669888) compiled data from 327 women across multiple trials investigating PRP for FSD and SUI.
[Systematic Review (PMC10669888) Summary]
│
├──> Enrollment: 327 women (Mean age 51)
│
├──> Sexual Dysfunction (FSD):
│ └──> FSFI & FSDS scores improved from baseline in uncontrolled cohorts.
│ └──> Lacked robust, double-blind, placebo-controlled validation.
│
└──> Stress Urinary Incontinence (SUI):
└──> ICIQ-SF & UDI-6 scores showed moderate reduction.
└──> Midurethral sling surgery remains statistically and clinically superior.
The review observed that while participants in uncontrolled, open-label cohorts reported improvements in their Female Sexual Function Index (FSFI) scores and reductions in the Female Sexual Distress Scale (FSDS), these trials lacked double-blind, placebo-controlled designs. Without a control group, it is impossible to separate the physiological effects of PRP from the substantial placebo effect associated with sexual dysfunction treatments.
For Stress Urinary Incontinence, the review noted that while PRP injections led to mild improvements in incontinence questionnaires (such as the UDI-6 and ICIQ-SF), traditional surgical interventions—specifically the placement of a midurethral sling—remained significantly superior to PRP in terms of both objective cure rates and long-term durability.
Does the P-Shot work for erectile dysfunction, and how good is the evidence?
The evidence supporting the P-Shot (intracavernosal PRP) for male erectile dysfunction (ED) is more robust than the female data, but it remains in the early stages of clinical adoption.
The Landmark Poulios RCT: Methodology and Parameters
The most critical trial in the male intimate PRP literature is the double-blind, randomized, placebo-controlled trial conducted by Poulios et al. (2021) [PMID 33906807]. This study represents the first high-quality, placebo-controlled trial designed to isolate the therapeutic effect of PRP on erectile function.
- Inclusion and Exclusion Criteria: The study enrolled 60 sexually active men aged 40 to 70 with mild to moderate vasculogenic erectile dysfunction (IIEF-EF scores spanning the mild-through-moderate range, roughly 11 to 25) persisting for more than 6 months. Patients were excluded if they had a history of pelvic surgery (including radical prostatectomy), pelvic trauma, neurological disease, or severe psychiatric disorders, or if they had used PDE5 inhibitors or intracavernosal injections within 4 weeks of the study.
- PRP Preparation and Platelet Parameters: For each treated patient, 60 mL of peripheral blood was drawn using acid citrate dextrose-A (ACD-A) as an anticoagulant. The blood was processed using the Magellan autologous platelet separator, which uses an automated dual-spin centrifugation protocol. The process yielded approximately 10 mL of leukocyte-poor PRP, achieving a 4.5-fold concentration of platelets over baseline (a therapeutic concentration of roughly 1.1 million platelets per microliter). The PRP was activated using 10% calcium chloride (0.1 mL per 1 mL of PRP) immediately before injection to trigger the rapid release of growth factors from alpha-granules.
- Injection Technique: The active group received two sessions of intracavernosal injections spaced 30 days apart. Under local anesthesia (using a topical eutectic mixture of lidocaine and prilocaine), 5 mL of the activated PRP was injected into each corpus cavernosum (total 10 mL) using a 27-gauge, 13-mm needle. A soft tourniquet was placed at the base of the penis for 15 minutes post-injection to prevent immediate systemic wash-out of the growth factors. The placebo group received an identical volume of sterile saline under the same protocol.
Clinical Efficacy and Outcome Metrics
The trial evaluated outcomes using the International Index of Erectile Function (IIEF) at 1, 3, and 6 months:
- IIEF-EF Score Changes: The mean baseline IIEF-EF score in the PRP group was 15.6. At the 6-month endpoint, the mean score rose to 20.4 (an increase of 4.8 points). In the placebo group, the mean baseline score was 15.1, rising to 16.3 at 6 months (an increase of 1.2 points). The baseline-adjusted difference between the groups was +3.9 points (95% CI 1.8 to 5.9), which is statistically and clinically significant.
- Minimal Clinically Important Difference (MCID): The primary endpoint was reaching the MCID — defined per standard IIEF-EF thresholds as a ≥2-point improvement for mild or mild-to-moderate ED (baseline IIEF-EF 17–25) or a ≥5-point improvement for moderate ED (baseline IIEF-EF 11–16). At 6 months, 69% (20 out of 29) of the PRP group achieved the MCID, compared to 27% (7 out of 26) of the placebo group.
- Flow Parameters: Doppler ultrasound of the cavernous arteries showed a mild, non-significant increase in peak systolic velocity (PSV) in the PRP group, suggesting that while some tissue remodeling occurred, the vascular change was modest.
- Safety Profile: No structural complications (such as Peyronie's disease, penile plaques, or severe curvature), no hematomas, and no systemic adverse events were reported during the study window.
Meta-Analysis and Long-Term Durability
A newer meta-analysis published in The Aging Male (Taylor and Francis, 2024) pooled data from 7 randomized controlled trials representing 660 male patients. The analysis concluded that intracavernosal PRP injections yielded statistically significant improvements in IIEF scores at 12 and 24 weeks compared to control groups.
Despite these positive findings, urological associations maintain a cautious stance:
- The American Urological Association (AUA): The AUA guidelines do not endorse PRP for the treatment of erectile dysfunction outside of clinical trials. The association classifies the treatment as investigational and experimental.
- The Sexual Medicine Society of North America (SMSNA): The SMSNA aligns with the AUA, emphasizing that while early RCTs (such as the Poulios study) show promise, the optimal concentration of platelets, the injection frequency, and the long-term durability of the treatment (beyond 6 to 12 months) remain unknown.
- Cleveland Clinic Guidance: Patient literature from the Cleveland Clinic notes that there is currently insufficient long-term scientific evidence to prove the P-Shot can reliably resolve erectile dysfunction, recommending that patients rely on established, FDA-approved medical therapies.
How much do the O-Shot and P-Shot cost, and does insurance cover them?
Because the O-Shot and P-Shot are performed off-label and are classified as investigational for sexual dysfunction, they are never covered by commercial health insurance or Medicare. Patients must pay the entire cost out of pocket.
- Typical Cost Per Session: Out-of-pocket pricing ranges from $1,200 to $3,000 per injection session, depending on the geographic market and the clinical credentials of the injector.
- The Package Model: Many med spas recommend an initial series of two to three sessions, followed by annual maintenance treatments. This structure can lead to an upfront cost of $3,600 to $9,000.
- Financial Comparison Against FDA-Approved Alternatives:
[Intimate PRP vs FDA-Approved Alternatives: Cost Comparison]
Intimate PRP (O-Shot / P-Shot)
$1,200 – $3,000 per session (Out of pocket; no insurance coverage)
──────────────────────────────────────────────────────────────────
Generic Sildenafil / Tadalafil (Erectile Dysfunction)
$10 – $50 per month (Often insurance-covered; 70-85% success in massive RCTs)
──────────────────────────────────────────────────────────────────
Surgical Midurethral Sling (Stress Urinary Incontinence)
Variable (Highly covered by insurance; high objective cure rates)
For patients deciding between elective regenerative options and traditional medical therapies, this cost disparity represents a significant factor. While oral medications and surgery have established side-effect profiles, their financial access and clinical certainty are supported by large-scale trials.
What are the real risks and adverse events reported with intimate PRP?
Because PRP is autologous (derived from the patient's own blood), the risk of allergic reaction, foreign-body response, or systemic rejection is virtually zero. This safety profile is frequently highlighted in clinic advertising. However, the procedure of injecting fluid into highly vascularized, sensitive genital tissues presents mechanical and localized risks.
The systematic review literature (such as PMC10669888) and clinical registries record several adverse events:
- Persistent Arousal (Women): The literature describes two cases of persistent, painful, and unwanted sexual arousal following clitoral/vaginal PRP injections (Runels et al.). This condition resolved spontaneously after several weeks but caused significant distress.
- Temporary Urinary Retention: One patient experienced acute urinary retention requiring temporary self-catheterization (Chiang et al.) due to localized swelling and hematoma formation in the urethrovaginal space.
- Penile Hematoma and Bruising (Men): Intracavernosal injections carry a risk of hematoma, localized pain, ecchymosis (bruising), and temporary swelling.
- Theoretical Fibrosis: Repeated needles entering the corpus cavernosum carry a small, theoretical risk of triggering Peyronie's-like plaque formation or localized fibrosis, which could worsen erectile dysfunction over time. However, this has not been observed in short-term clinical trials.
Clinical Protocol: Risk Mitigation Workflow
To minimize these risks, clinical practices follow a structured procedural safety protocol:
- Pre-Procedural Antisepsis: Intimate skin must be prepared using chlorhexidine gluconate or povidone-iodine. Alcohol-based solutions should be avoided on mucosal tissue due to irritation.
- Anesthetic Block: Rather than aggressive infiltration of local liquid lidocaine (which adds volume and increases post-procedural edema and SUI/retention risk), clinics use topical eutectic mixtures of lidocaine/prilocaine (EMLA) applied under occlusion for 30–45 minutes, occasionally supplemented by a dorsal penile nerve block for men or a pudendal block for women.
- Post-Injection Hemostasis: Immediately after injection, firm, continuous manual pressure must be applied to the injection site for 3 to 5 minutes to prevent hematoma formation. For men, a light cohesive compression wrap may be applied to the shaft for 2 to 3 hours.
- Post-Procedural Activity Restrictive Matrix:
- Sexual Intercourse: Complete abstinence from vaginal, oral, or anal intercourse for 48 hours post-injection to allow the needle tracts to close and reduce the risk of introducing bacteria.
- Exercise and Physical Activity: Restrict vigorous cardio, heavy lifting, bicycling, or horseback riding for 48 hours to prevent vascular pressure changes that could promote hematoma.
- Hygiene and Bathing: Avoid hot tubs, swimming pools, baths, or saunas for 48 hours to prevent contamination of the micro-punctures; standard showers are permitted.
Clinical Registry Analysis: The Aesthetic Trial Landscape
To characterize the broader landscape of clinical research, we screened a clinical trial registry dataset containing 2,506 registered clinical trials matched on aesthetic and dermatological terms. The audit aimed to quantify the volume of intimate regenerative trials:
- PRP & Intimate Match Counts: Out of the 2,506 trials, only 58 studies contained keywords relating to platelet-rich plasma, vaginal rejuvenation, sexual dysfunction, or erectile dysfunction.
- Trial Focus: The majority of the 58 matching studies were focused on non-genital indications, such as:
- NCT02591355: Platelet-rich plasma for androgenetic alopecia (hair loss).
- NCT03647917: PRP for skin rejuvenation (facial and hand tissue remodeling).
- Intimate Dermal Fillers: Studies like NCT04659668, NCT06797167, and NCT07402395 investigated hyaluronic acid fillers for female intimate tissue reconstruction or laxity, representing a different therapeutic class.
- Under-Representation of O-Shot/P-Shot Registrations: We confirmed that dedicated, independent trials evaluating the O-Shot or P-Shot for female sexual dysfunction (such as NCT06028009 or NCT05769283) are not captured in local aesthetic aggregates. This lack of registry data emphasizes the need for clinicians and patients to consult primary registries (ClinicalTrials.gov) and peer-reviewed journals, rather than relying on generalized aesthetic trial summaries.
For an overview of how PRP compares with other regenerative therapeutics, see our guide on PDRN vs PRP vs exosomes. To understand the evidence base for hair and skin applications, read our PRP for skin and hair restoration reference.
How does intimate PRP compare with FDA-approved alternatives?
When evaluating the O-Shot or P-Shot, patients should compare them directly to established, FDA-approved therapeutic pathways.
Female Sexual Dysfunction & Incontinence Alternatives
- Vaginal Estrogen Therapy: For Genitourinary Syndrome of Menopause (GSM), low-dose topical estrogen creams are FDA-approved and show high efficacy for resolving dryness, dyspareunia, and mild urinary irritation.
- Energy-Based Devices: Laser and radiofrequency (RF) vaginal rejuvenation devices are also used off-label for GSM, but they are supported by separate clinical trials. To compare these modalities, review our analysis on vaginal rejuvenation and GSM energy devices.
- Pelvic Floor Physical Therapy: The first-line, risk-free therapy for stress urinary incontinence.
Male Erectile Dysfunction Alternatives
- Oral PDE5 Inhibitors: Sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) are first-line therapies. They work by enhancing nitric oxide-mediated vasodilation. Large-scale RCTs show efficacy rates of 70% to 85%, which exceeds the current early trial response rates of PRP.
- Vacuum Erection Devices (VEDs): A non-invasive mechanical option.
- Penile Prostheses: A surgical option reserved for severe, refractory erectile dysfunction.
FAQs
Is the O-Shot FDA-approved?
No. The O-Shot procedure itself is not FDA-approved. The centrifuge devices used by clinics to spin and prepare the platelet-rich plasma are FDA 510(k)-cleared for orthopedic and wound-healing indications, but using them to treat female sexual function is an off-label clinical application.
How long do O-Shot or P-Shot results last?
Clinical providers claim that the effects of a single PRP session last between 12 and 18 months. However, because there are no long-term, multi-year placebo-controlled trials, this duration is based on anecdotal clinic reporting. In the Poulios RCT, erectile function improvements were tracked only up to 6 months, leaving the long-term durability of the therapy unproven.
Can the P-Shot replace Viagra or Cialis?
For some patients with mild vasculogenic ED, the P-Shot may provide sufficient tissue recovery to reduce reliance on oral medications. However, for patients with moderate-to-severe ED, nerve damage (such as post-prostatectomy), or severe arterial insufficiency, PRP is unlikely to replace PDE5 inhibitors. It should be viewed as an experimental adjunct rather than a first-line cure.
Are there serious risks from injecting PRP into genital tissue?
While severe systemic complications are extremely rare, localized risks include bruising, swelling, penile hematoma, and infection. The literature also records rare cases of temporary urinary retention in women and persistent, painful arousal. Patients must ensure the procedure is performed by a licensed medical provider using sterile techniques in a clinical environment.
Why do clinics claim 90% success if the studies do not?
Many clinics rely on internal, retrospective questionnaires filled out by patients shortly after treatment, which are highly susceptible to placebo effects and selection bias. Furthermore, the trademarked training groups often bundle PRP with counseling, pelvic floor guidance, or vacuum therapy, making it difficult to isolate the true efficacy of the PRP injection itself. For a detailed critique of how marketing claims can diverge from clinical trial endpoints, see our analysis on when med-spa marketing outruns the evidence.
Sources
- National Center for Biotechnology Information (NCBI) PMC: Efficacy and Safety of PRP Injections for Female Sexual Dysfunction and Stress Urinary Incontinence: A Systematic Review. PMC10669888
- National Center for Biotechnology Information (NCBI) PubMed: Platelet-Rich Plasma (PRP) Improves Erectile Function: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial (Poulios 2021). PMID 33906807
- ClinicalTrials.gov: PRP Injections for Genitourinary Syndrome of Menopause (NCT06028009). NCT06028009
- Sexual Medicine Society of North America (SMSNA): What Is the P-Shot? Does It Actually Work? https://www.smsna.org/patients/did-you-know/what-is-the-p-shot-does-it-actually-work
- Cleveland Clinic: Priapus Shot (P-Shot): PRP, How It Works, Benefits and Risks. https://my.clevelandclinic.org/health/treatments/p-shot
- National Center for Biotechnology Information (NCBI) PMC: Erectile Dysfunction: Is Platelet-Rich Plasma the New Frontier? A Review of the Existing Evidence. PMC9580815
- Taylor & Francis Online: Efficacy of Platelet-Rich Plasma in Erectile Dysfunction: A Meta-Analysis of RCTs. The Aging Male (2024)
- Oklahoma State University Center for Health Sciences: Evaluating Clinical Trials using Platelet-Rich Plasma to Treat Female Sexual Dysfunction. OSU Research Registry
